Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

NCT01855490 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication exenatide affects blood sugar responses to meals or glucose injections in adults with type 1 diabetes, with or without remaining insulin production.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 17 people

Who can join Ages 18–56 · all sexes

Timeline Started 2012-01 · est. completion 2013-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01855490 ↗

Description as written by the study sponsor.

The study is designed as an open labeled pilot trial to analyze the acute responses of glucose, GLP-1, GIP, insulin secretory,and glucagon to a mixed meal tolerance test (MMTT) or intravenous glucose tolerance tests (IVGTT) with and without pretreatment with Exenatide (Byetta) 5 mcg sc. The investigators will also test the effects of Exenatide on gastric emptying during the MMTT.

Treatments tested

Exenatide Drug

Main thing measured	Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.
Sponsor	Yale University
Conditions studied	Type 1 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01855490 ↗